Oxycodone: a review of its use in the management of pain

References

• Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic cancer pain. Eur J Pain 2003;7:379–80
   PubMed Web of Science ®Google Scholar
• The British Pain Society. Recommendations for the appropriate use of opioids in persistent non-cancer pain 2004. Available from http://www.britishpainsociety.org/book_opioid_main.pdf [Last accessed 30 October 2007]
   Google Scholar
• Ventafridda V, Saita L, Ripamonti C, et al. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 1985;7:93–6
   PubMedGoogle Scholar
• Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989;27:499–505
   PubMed Web of Science ®Google Scholar
• Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled- release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239–49
   Google Scholar
• Kwarcinski M. Conversion ratio and cost of oxycodone. Am J Hospice Palliat Care 2001;18:159–60
   PubMedGoogle Scholar
• Kalso E, Poyhia R, Onnela P, et al. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesth Scand 1991;35:642–6
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64: 603–11
   Google Scholar
• Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461–79
   PubMed Web of Science ®Google Scholar
• Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102–5
   PubMed Web of Science ®Google Scholar
• Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001–6
   PubMed Web of Science ®Google Scholar
• Reder RF, Oshlack B, Miotto JB, et al. Steady-state bioavailability of controlled-released oxycodone in normal subjects. Clin Ther 1996;18:95–105
   PubMed Web of Science ®Google Scholar
• Curtis GB, Johnson GH, Clark P, et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999;55:425–9
   PubMed Web of Science ®Google Scholar
• Colucci RD, Swanton RE, Thomas GB, et al. Retrospective analysis of relative variability of controlled-release oxycodone and morphine absorption in normal volunteers. J Clin Pharmacol 1998;38:875
   Google Scholar
• Kalso E. Oxycodone. J Pain Symptom Manage 2005;29 (Suppl):S47–56
   Google Scholar
• Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic- pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52–61
   PubMed Web of Science ®Google Scholar
• Levy MH. Advancement of opioid analgesia with controlled- release oxycodone. Eur J Pain 2001;5(Suppl A):113–6
   Google Scholar
• Mandema JW, Kaiko RF, Oshlack B, et al. Characterisation and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747–56
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board. Annual Report 2006. Available from http://www.incb.org/pdf/e/ar/2006/annual- report-2006-en-pdf [Last accessed 22 August 2007]
   Google Scholar
• Suleman R, Abourjaily H, Rosenberg M. Oxycontin – misuse and abuse. J Mass Dent Soc 2002;51:56–8
   PubMedGoogle Scholar
• Sees KL, Marino ME, Ruediger NK, et al. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother 2005;19:13–23
   PubMedGoogle Scholar
• OxyContin summary of product characteristics. Electronic medicine compendium, 2005. Available from http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2579 [Last accessed 10 February 2006]
   Google Scholar
• Kaiko RF.Pharmacokineticsandpharmacodynamicsofcontrolled- release opioids. Acta Anaesthesiol Scand 1997;41:166–74
   PubMed Web of Science ®Google Scholar
• Tallgren M, Olkkola KT, Seppala T, et al. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997;61:655–61
   PubMed Web of Science ®Google Scholar
• Kirvela M, Lindgren L, Seppala T, et al. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996;8:13–8
   PubMed Web of Science ®Google Scholar
• Poyhia R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993;8:63–7
   Google Scholar
• Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73:151–7
   PubMed Web of Science ®Google Scholar
• Nozaki C, Saitoh A, Tamura N, et al. Antinociceptive effect of oxycodone in diabetic mice. Eur J Pharmacol 2005;524:75–9
   PubMed Web of Science ®Google Scholar
• Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine has distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007 [Epub ahead of print 27 Apr 2007]
   Google Scholar
• Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 2000;295:91–9
   Google Scholar
• Riviere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004;141:1331–4
   PubMed Web of Science ®Google Scholar
• Simonin F, Valverde O, Smadja C, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50488H and attenuates morphine withdrawal. EMBO J 1998;17:886–97
   PubMed Web of Science ®Google Scholar
• Staahl C, Christrup LL, Andersen SD, et al. A comparative study of oxycodone and morphine in a multimodal, tissue differentiated experimental pain model. Pain 2006;123:28–36
   PubMed Web of Science ®Google Scholar
• Staahl C, Dimcevski AM. Anderson S, Thorsgaard N, et al. Differential effects of opioids in patients with chronic pancreatitis: An experimental study. Scand J Gastroenterol 2007;42:383–90
   PubMed Web of Science ®Google Scholar
• Khotib J, Narita M, Suzuki M, et al. Functional interaction among opioid receptor types: up-regulation of mu- and delta- opioid receptor functions after repeated stimulation of kappa- opioid receptors. Neuropharmacology 2004;46:531–40
   PubMed Web of Science ®Google Scholar
• Chabre M, Cone R, Saibil H. Biophysics: is rhodopsin dimeric in native retinal rods? Nature 2003;426:30–1 discussion 31
   Google Scholar
• Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharm 2006;60:310–7
   PubMed Web of Science ®Google Scholar
• Band IC, Pert A, Williams W. Central mu opioid receptors mediate suppression of natural killer cell activity in vivo. Prog Neuroendocrinol 1992;5:95
   Google Scholar
• Sacerdote P, Manfredi B, Mantegazza P, et al. Antinociceptive and immunosuppressive effects of opiate drugs: a structure- related activity study. Br J Pharmacol 1997;121:834–40
   PubMed Web of Science ®Google Scholar
• Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomised trial in postherpetic neuralgia. Neurology 1998;50:1837–41
   PubMed Web of Science ®Google Scholar
• Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 2003;60:927–34
   Google Scholar
• Watson CP, Moulin D, Watt-Watson J, et al. Controlled- release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105: 71–8
   Google Scholar
• Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 2006;10:667–76
   Google Scholar
• Wörz R, Frank M, Achenbach U. Controlled-release oxycodone – a therapeutic option for severe neuropathic pain. Two multicenter observational studies [in German]. MMW Fortschr Med 2003;145(Suppl 3):71–6
   Google Scholar
• Wallasch TM. Oxycodone retard in a patient suffering from a polyneuropathy with burning dysaesthesia [in German]. Neurol Rehabil 2002;8:208–10
   Google Scholar
• Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289–305
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215–24
   Google Scholar
• Wiffen PJ, McQuay HJ, Edwards JE. Gabapentin for acute and chronic pain. The Cochrane Database of Systematic Reviews 2005, Issue 3: CD005452
   Google Scholar
• Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. The Cochrane Database of Systematic Reviews 2005, Issue 3: CD005454
   Google Scholar
• Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–34
   PubMed Web of Science ®Google Scholar
• Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain. Placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853–60
   Web of Science ®Google Scholar
• Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998;41:1603–12
   PubMed Web of Science ®Google Scholar
• Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflam- matory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862–9
   PubMed Web of Science ®Google Scholar
• McCroskery E, Croft J, Markenson J. 3-month efficacy and safety study of OxyContin in osteoarthritis patients. Proceedings of EFIC; 26–29 September 2000; Nice, France
   Google Scholar
• Markenson JA, Croft J, Zhang PG, et al. Treatment of persistent pain associated with osteoarthritis with controlled- release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005;21:524–35
   PubMed Web of Science ®Google Scholar
• Zautra AJ, Bruce BW. Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 2005;21:471–7
   PubMed Web of Science ®Google Scholar
• Hale M, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15:179–83
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Galer BS, Lacouture P, et al. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 2003;4:21–30
   PubMed Web of Science ®Google Scholar
• Überall MA, Mueller-Schwefe G. Untreated pain- optimizing multidisciplinary rehabilitation programs in high-risk patients with chronic low back pain using WHO-III opioid oxycodone. Abstracts, 11th World Congress on Pain; 21–26 August 2005, Sydney, Australia
   Google Scholar
• Krämer J, Theodoridis T, Gawora K. Effective and safe treatment of lumbar root compression syndrome with sustained-release oxycodone. Abstracts, 11th World Congress on Pain; 21–26 August 2005, Sydney, Australia
   Google Scholar
• Cancer pain relief. 2nd Edn. With a guide to opioid availability. WHO, 1996. Available from http://whqlibdoc.who.int/publications/9241544821.pdf [Last accessed 16 January 2007]
   Google Scholar
• Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589–94
   Google Scholar
• Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986;25:171–86
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372–80
   PubMed Web of Science ®Google Scholar
• OxyNorm summary of product characteristics. Napp Pharmaceuticals, 2006. Available from http://www. palliativedrugs.com/content/website/napp/OxyNorm.php [Last accessed 10 July 2006]
   Google Scholar
• Reuben SS, Connelly NR, Maciolek H. Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 1999;88:1286–91
   Google Scholar
• Cheville A, Chen A, Oster G, et al. A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg 2001;83A:572–6
   Web of Science ®Google Scholar
• Richards P, Colucci S, Scuderi G, et al. Pain control and functional recovery with CR Oxycodone vs usual care following total knee replacement. 21st Annual Meeting of the American Academy of Pain Medicine 23–27 Feb 2005. Palm Springs, USA
   Google Scholar
• Kaufmann J, Yesiloglu S, Patermann B, et al. Controlled-release oxycodone is better tolerated than intravenous tramadol/ metamizol for postoperative analgesia after retinal-surgery. Curr Eye Res 2004;28:271–5
   PubMed Web of Science ®Google Scholar
• Wirz S, Wartenberg HC, Wittman M. Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopedic surgery: a prospective, randomized, double-blind investigation. The Pain Clinic 2005;17:367–76
   Google Scholar
• de Beer Jde V, Winemaker MJ, Donnelly GA, et al. Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg 2005;48:277–83
   PubMed Web of Science ®Google Scholar
• Hohwü L, Akre O, Bergenwald L, et al. Oral oxycodone hydro- chloride vs. epidural anaesthesia (EDA) for pain control after radical retropubic prostatectomy (RRP). European Associa- tion of Urology, Paris, France 2006. Scand J Urol Nephrol 2006;40: 192–7
   Google Scholar
• Czarnecki ML, Jandrisevits MD, Theiler SC, et al. Controlled- release oxycodone for the management of pediatric postoperative pain. J Pain Symptom Manage 2004;27:379–86
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain. Visceral pain. Pain. Clinical updates. Volume 13, no. 6. December 2005
   Google Scholar
• Zondervan KT, Yudkin PL, Vessey MP, et al. The prevalence of chronic pelvic pain in women in the United Kingdom: a systematic review. Br J Obstet Gynaecol 1998;105:93–9
   PubMedGoogle Scholar
• Russo MW, Wei JT, Thiny MT, Gangarosa LM, et al. Digestive and liver disease statistics, 2004. Gastrotenterology 2004;126:1448–53
   PubMed Web of Science ®Google Scholar
• Zondervan KT, Yudkin PL, Vessey MP, et al. Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. Br J Obstet Gynaecol 1999;106:1149–55
   PubMedGoogle Scholar
• Hunt RH, Dhaliwal S, Tougas G, Pedro C, et al. Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: a descriptive study. Can J Gastroenterol 2007;21:31–7
   PubMed Web of Science ®Google Scholar
• Drewes AM, Schipper KP, Dimcevski G, et al. Multimodal assessment of pain in the esophagus: a new experimental model. Am J Physiol Gastrointest Liver Physiol 2002;283:G95–103
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L. Induction and assessment of experimental pain from human skin, muscle and viscera. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, editors. Proceedings of the 8th World Congress on Pain, Vancouver, Canada, 17–22 August 1996. Progress in pain research and management. Seattle: IASP Press, 1997. pp.393–425
   Google Scholar
• Staahl C, Drewes AM. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 2004;95:97–111
   PubMed Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383–94
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29(Suppl):S2–9
   Google Scholar
• Sunshine A, Olson NZ, Colon A, Rivera J, et al. Analgesic efficacy of controlled-release oxycodone in postoperative pain. J Clin Pharmacol 1996;36:595–603
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Edwards JE, Barden J, et al. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews: CD003868, 2003. Available from http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003868/frame.html [Last accessed 15 October 2007]
   Google Scholar
• International Narcotics Control Board. Consumption of the principal narcotic drugs, 2005. Statistics for 2004. Available from http://www.incb.org/incb/en/narcotic_drugs_2005.html [Last accessed 30 October 2007]
   Google Scholar
• Reid CM, Martin RM, Sterne JAC, et al. Oxycodone for cancer related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:837–43
   PubMed Web of Science ®Google Scholar
• Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006;14:56–64
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, et al. Randomized, double- blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16:3222–9
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73:37–45
   PubMed Web of Science ®Google Scholar
• Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428–37
   PubMed Web of Science ®Google Scholar
• Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained- release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89:2027–30
   Google Scholar
• Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998;16:3230–7
   PubMed Web of Science ®Google Scholar
• Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate- release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18:271–9
   PubMed Web of Science ®Google Scholar
• Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41:500–6
   PubMed Web of Science ®Google Scholar
• Citron ML, Kaplan R, Parris WC, et al. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest 1998;16:562–71
   PubMed Web of Science ®Google Scholar
• Koizumi W, Toma H, Watanabe K, et al. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naïve cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol 2004;34:608–14
   PubMed Web of Science ®Google Scholar
• Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639–46
   PubMed Web of Science ®Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arth Res Ther 2005;7:R1046–51
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler D. Opioid-induced bowel dysfunction. Drugs 2003;63:649–71
   PubMed Web of Science ®Google Scholar
• Yuan C-S, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use. JAMA 2000;283:367–72
   Google Scholar
• Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomised controlled study. Clin Gastroenterol Hepatol 2005;3:784–91
   PubMed Web of Science ®Google Scholar
• Meissner W, Schmidt U, Hartmann M. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105–9
   Google Scholar
• Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64: 603–11
   Google Scholar